ArticleDrug delivery and translational research2012
Development of quercetin nanoformulation and in vivo evaluation using streptozotocin induced diabetic rat model.
Article in Drug delivery and translational research, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed.
- The effect of crocin-selenium nanoparticles on the cognition and oxidative stress markers of multiple sclerosis patients: a randomized triple-blinded placebo-controlled clinical trial.Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine · 2024Trial
- Nanotechnology-Based Plant Antioxidants: A Current Literature Review on Bioavailability and Oxidative Stress.Current nutrition reports · 2025Review
- How do nanoparticle properties shape pharmacokinetics and pharmacodynamics? A mechanistic review.Frontiers in pharmacology · 2025Review
- Anti-inflammatory potential of quercetin: From chemistry and mechanistic insight to nanoformulations.Current research in pharmacology and drug discovery · 2025Review
- Nanoquercetin based nanoformulations for triple negative breast cancer therapy and its role in overcoming drug resistance.Discover oncology · 2024Review
- Novel combination of Olesoxime/Resveratrol-encapsulated exosomes to improve cognitive function by targeting amyloid β-induced Alzheimer's disease: investigation on in vitro and in vivo model.Inflammopharmacology · 2024Article
- Multiple nanotechnological approaches using natural compounds for diabetes management.Journal of diabetes and metabolic disorders · 2024Review
- A Comprehensive Review on Prospects of Polymeric Nanoparticles for Treatment of Diabetes Mellitus: Receptors-Ligands,Recent patents on nanotechnology · 2024Review
- Review
- Investigating Polyphenol Nanoformulations for Therapeutic Targets against Diabetes Mellitus.Evidence-based complementary and alternative medicine : eCAM · 2022Review
- A Review on Obesity Management through Natural Compounds and a Green Nanomedicine-Based Approach.Molecules (Basel, Switzerland) · 2021Review
- Role of Nanotechnology and Their Perspectives in the Treatment of Kidney Diseases.Frontiers in genetics · 2021Review
- Role of the Encapsulation in Bioavailability of Phenolic Compounds.Antioxidants (Basel, Switzerland) · 2020Review
- Recent Advances in Nanoencapsulation of Phytochemicals to Combat Obesity and Its Comorbidities.Journal of agricultural and food chemistry · 2020Review
- Article
- Plant-Based Antidiabetic Nanoformulations: The Emerging Paradigm for Effective Therapy.International journal of molecular sciences · 2020Review
- Review
- Oral Nano Drug Delivery Systems for the Treatment of Type 2 Diabetes Mellitus: An Available Administration Strategy for Antidiabetic Phytocompounds.International journal of nanomedicine · 2020Review
- Article
- Nanodelivery of Natural Antioxidants: An Anti-aging Perspective.Frontiers in bioengineering and biotechnology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Quercetin-loaded poly(lactic-co-glycolic acid) (PLGA) nanoparticles (Qu-NP) were prepared by emulsion-diffusion-evaporation method and characterized as 179.9 ± 11.2 nm in size with 0.128 as polydispersity index, more than 86% drug entrapment efficiency, and zeta potential was -6.06 ± 1.51 mV. D-Trehalose (5% w/v) was found to be a suitable cryoprotectant for lyophilization of Qu-NP, and antioxidant assays indicated that Qu-NP were able to retain the antioxidant property similar to that of free drug at equivalent concentration after formulation development. In vitro release study of Qu-NP showed a controlled release pattern of quercetin. An enhanced oral bioavailability (523% relative increase) was observed in pharmacokinetic study with a 6-day sustained release from Qu-NP as compared to quercetin suspension, which indicated the reduced dosing frequency. Efficacy in diabetic rats suggested that same dose of Qu-NP on every fifth day was sufficient to bring effect similar to daily dose of oral quercetin suspension, and the same effect was also observed for catalase and superoxide dismutase levels in pancreas and kidneys. Thus, the system offers an efficacious oral therapy with reduced dose and dosing frequency for treatment of diabetes and is hence patient compliant.
Identifiers
25786720What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.